EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Novel biopharmaceutical strategies: Fc-fusion protein technology

Xin-Yuan Ding, Hong-Li Fan, Chun-Miao Zhang, Meng-Xiao Wei, Zhe-Zheng Lin, Cai-Juan Bai, Ming-Yu Wang, Hai-Hong Zhou

Frontiers in Pharmacology · 16.07.2026 · 17

DOI: 10.3389/fphar.2026.1853458 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Frontiers in Pharmacology, online erschienen am 16.07.2026. Verfasst von Xin-Yuan Ding und 7 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Translational Medicine, Gansu Provincial Academic Institute for Medical Research, Lanzhou, China. Die Arbeit nennt 99 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Therapeutic proteins represent pivotal interventions for diverse pathologies but face inherent limitations, including a short serum half-life and suboptimal stability. Fc-fusion protein technology, an innovative biopharmaceutical approach, conjugates functional protein domains to the IgG Fc fragment via engineered linkers. By exploiting FcRn-mediated recycling and enhanced thermodynamic stability, this strategy extends the circulatory half-life. Concurrently, interactions with FcγRs and complement component 1q (C1q) confer Fc-fusion proteins immunomodulatory functions, for example, antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). Recent clinical approvals of novel Fc-fusion biologics underscore the translational viability of Fc-fusion proteins. With ongoing innovations in artificial intelligence-guided design and engineered Fc scaffolds, Fc-fusion technology is positioned to dominate next-generation biotherapeutics. Notwithstanding advantages in pharmacokinetics, challenges such as target-mediated drug disposition (TMDD) and FcRn binding interference still need to be addressed. This study systematically evaluates the current status of Fc-fusion protein drugs and recent engineering advancements to enhance the application of Fc-fusion proteins in drug development.

Schlagwörter

Stichwörter der Autor:innen

Fc-fusion proteinsengineering advanceshalf-lifeimmunomodulatory functionsstability

Autor:innen und Institutionen

  • Centre for Translational Medicine, Gansu Provincial Academic Institute for Medical Research, Lanzhou, China.
  • Centre for Translational Medicine, Sun Yat-sen University Cancer Center Gansu Hospital, Lanzhou, China.
  • MOE Key Laboratory of Cell Activities and Stress Adaptations, School of Life Sciences, Lanzhou University, Lanzhou, China.
  • The Core Facility, School of Basic Medical Sciences, Lanzhou University, Lanzhou, China.
  • NHC Key Laboratory of Diagnosis and Therapy of Gastrointestinal Tumor, Gansu Provincial Hospital, Lanzhou, China.
  • Institute of Clinical Research and Translational Medicine, Gansu Provincial Hospital, Lanzhou, China.

Zitieren

APA

Ding, X. Y., Fan, H. L., Zhang, C. M., Wei, M. X., Lin, Z. Z., Bai, C. J., Wang, M. Y., & Zhou, H. H. (2026). Novel biopharmaceutical strategies: Fc-fusion protein technology. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.1853458

Vancouver

Ding XY, Fan HL, Zhang CM, Wei MX, Lin ZZ, Bai CJ, et al. Novel biopharmaceutical strategies: Fc-fusion protein technology. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.1853458

BibTeX
@article{Ding2026,
  author = {Ding, Xin-Yuan and Fan, Hong-Li and Zhang, Chun-Miao and Wei, Meng-Xiao and Lin, Zhe-Zheng and Bai, Cai-Juan and Wang, Ming-Yu and Zhou, Hai-Hong},
  title = {Novel biopharmaceutical strategies: Fc-fusion protein technology},
  journal = {Frontiers in Pharmacology},
  year = {2026},
  volume = {17},
  doi = {10.3389/fphar.2026.1853458}
}
Kostenlos starten →